Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Inlcuding Drugs that are Regulated Under a Biologics License Application, and Animal Drugs; Proposed Rule

ICR 200610-0910-001

OMB: 0910-0829

Federal Form Document

Forms and Documents
Document
Name
Status
Proposed Rule Document
2006-09-07
Supplementary Document
2006-08-31
Supporting Statement A
2006-09-07
ICR Details
0910-0829 200610-0910-001
Historical Inactive
HHS/FDA
Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Inlcuding Drugs that are Regulated Under a Biologics License Application, and Animal Drugs; Proposed Rule
New collection (Request for a new OMB Control Number)   No
Regular
Comment filed on proposed rule 01/04/2007
Retrieve Notice of Action (NOA) 10/05/2006
The information collection requirements associated with this proposed rule are not approved at this time. FDA will consider comments received from the public on the proposed information collection requirements contained in the rule and will resubmit at the final rule stage.
  Inventory as of this Action Requested Previously Approved
36 Months From Approved
0 0 0
0 0 0
0 0 0

21 CFR part 207 implements section 510 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360), under which FDA is authorized to establish a system for registration of producers of drugs and for listing of drugs in commercial distribution.

US Code: 21 USC 360 Name of Law: Federal Food, Drug, and Cosmetic Act
  
None

0910-AA49 Proposed rulemaking 71 FR 51276 08/29/2006

No

Yes
Changing Regulations
Yes
Changing Regulations
The proposed rule would reorganize, consolidate, clarify, and modify current regulations on registering establishments and listing human and animal drugs under 21 CFR 207, blood and blood products under part 607, and HCT/Ps under part 1271. The proposal describes when and how to register and list and what information must be submitted for registration and listing. The proposal makes certain changes to the NDC system for drugs and would require the appropriate NDC number to appear on drug labels (for drugs subject to the drug listing requirements). The proposed regulations would require the electronic submission of all registration and most listing information instead of the current use of paper forms.

$7,500,000
No
No
Uncollected
Uncollected
Uncollected
Uncollected
Saleda Perryman

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
09/27/2006


© 2024 OMB.report | Privacy Policy